Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7180177 | 0.93 | HSP90AA1 (0.54) | FNTAFNTBHSP90AA1CES1CES2 | |
| SCHEMBL21060856 | 0.91 | HSP90AA1 (0.57) | HSP90AA1CES1CES2EPHX2FAAH | |
| SCHEMBL28194397 | 0.91 | HSP90AA1 (0.52) | FNTAFNTBHSP90AA1CES1CES2 | |
| SCHEMBL7184916 | 0.91 | HSP90AA1 (0.57) | HSP90AA1CES1CES2EPHX2FAAH | |
| SCHEMBL11649466 | 0.91 | HSP90AA1 (0.57) | HSP90AA1CES1CES2EPHX2FAAH | |
| SCHEMBL7185340 | 0.91 | HSP90AA1 (0.57) | HSP90AA1CES1CES2EPHX2FAAH | |
| SCHEMBL177558 | 0.86 | HDAC3 (0.50) | FNTAFNTBCES1CES2EPHX2 | |
| SCHEMBL8087887 | 0.84 | HDAC3 (0.48) | FNTAFNTBCES1CES2EPHX2 | |
| SCHEMBL7527834 | 0.84 | HDAC3 (0.48) | FNTAFNTBCES1CES2EPHX2 | |
| SCHEMBL7468860 | 0.82 | HSP90AA1 (0.45) | HSP90AA1CES1CES2EPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | claimed |
| EP-2176282-B1 | 8-BETA-SUBSTITUTED 16.ALPHA.-FLUORO-ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | Bayer Pharma AG (DE) | 2012-08-22 | — | — | EP | disclosed |
| EP-2176282-A2 | 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090029957-A1 | 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| WO-2009007454-A2 | 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014672-A1 | 8-beta-substituted estratrienes as selectively active estrogens | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | PETERS OLAF | 2008-07-31 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| US-7378404-B2 | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-05-27 | — | — | US | disclosed |
| US-6958327-B1 | 18 Norsteroids as selectively active estrogens | SCHERING, AG (DE) | 2005-10-25 | — | — | US | disclosed |
| US-20050065135-A1 | 8beta-Vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-trienes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040029847-A1 | 8Beta-substituted-11-beta-pentyl-and 11-beta-hexyl-estra-1,3,5(10)-triene derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-20030176405-A1 | 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | SCHERING AG (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| EP-1169336-A1 | ENT-STEROIDS AS SELECTIVELY ACTIVE ESTROGENS | Schering Aktiengesellschaft (DE) | 2002-01-09 | — | — | EP | disclosed |
| CN-1290642-A | Packaging and forming method using photographic image | EASTMAN KODAK CO (US) | 2001-04-11 | — | — | CN | disclosed |
| WO-2000063228-A1 | ENT-STEROIDS AS SELECTIVELY ACTIVE ESTROGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | ESR2, ESR1, ESRRA | FNTA 2196/4885FNTB 1809/4885HSP90AA1 4362/4885 |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | FNTA 1589/4885FNTB 2007/4885HSP90AA1 4286/4885 |
| US-20040029847-A1 | 8Beta-substituted-11-beta-pentyl-and 11-beta-hexyl-estra-1,3,5(10)-triene derivatives | GPER1, ESRRA, ESR2 | FNTA 1026/4885FNTB 1375/4885HSP90AA1 4259/4885 |
| US-20050065135-A1 | 8beta-Vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-trienes | CYP19A1, HSD17B11, ESR2 | FNTA 923/4885FNTB 1257/4885HSP90AA1 4000/4885 |
| US-20090029957-A1 | 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESR1, GPER1, ESR2 | FNTA 877/4885FNTB 1531/4885HSP90AA1 3435/4885 |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | CYP19A1, HSD17B11, GPER1 | FNTA 1379/4885FNTB 2483/4885HSP90AA1 4385/4885 |
| US-20030176405-A1 | 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens | ESR2, ESRRA, ESRRB | FNTA 1697/4885FNTB 1682/4885HSP90AA1 4410/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | FNTA 1003/4885FNTB 1292/4885HSP90AA1 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.